Luc Thomas

enseignant-chercheur

Centre de Recherche en Cancérologie de Lyon
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (18)

Year:

2026

Year:

2026

Year:

2026

Background Melanoma accounts for more than 75% of skin cancer‐related mortality. Dermatoscopy is an evidence‐based technique for earlier detection, yet differentiating melanocytic lesions remains challenging. Sub‐UV reflectance dermatoscopy (sUVRD) uses purple light (405 nm) to visualise chromophore distribution in the skin. Objectives This study aimed to evaluate whether the visibility of pigment network in melanomas is reduced under sub‐UV reflectance dermatoscopy (sUVRD) compared to polarised dermatoscopy (PD), and to assess this as a potential diagnostic clue for malignancy in melanocytic lesions. Methods We retrospectively analysed routinely collected medical images of pathology‐confirmed non‐acral non‐facial melanomas and clinically/dermatoscopically typical nevi in consecutive adult patients seen at Centre Léon Berard from 13 July 2023 to 28 October 2024. Only quality images displaying a pigmented network in at least one quadrant in PD were included. Three blinded raters with varying dermatoscopic experience (10+, 5+, < 1 years) assessed whether pigment network visibility under sUVRD was reduced or equal compared to PD. Results Among 39 patients (M/F ratio 1.29), 20 melanomas and 20 nevi were analysed. Pigment network visibility under sUVRD was significantly more reduced in melanomas versus nevi (60% vs. 20%; Chi‐square p = 0.024; OR = 6; sensitivity 0.6; specificity 0.8; PPV 0.75; NPV 0.67; Fragility index 2). Inter‐rater concordance was moderate (Fleiss' kappa 0.41). Conclusions In this preliminary study, reduced pigment network visibility under sUVRD compared to PD showed promise as a clue to differentiate melanomas from nevi displaying dermatoscopic network, with an odds ratio superior to most common melanoma criteria. Further validation on larger datasets with pathology‐confirmed lesions and standardised imaging conditions is required.

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Background: Melanoma constitutes an increasing global health burden. In the light of a growing shortage of dermatologists in several countries, primary care has emerged as an optimal setting for skin cancer screening. Historically, in France, skin cancer detection was typically managed by dermatologists, while general practitioners (GPs) were barely involved. In 2021, the Association of French GPs practicing Dermoscopy was created to address this gap by promoting and legitimizing dermoscopy practice among primary care physicians. Objectives: To assess the number of melanomas detected by dermoscopy-trained GPs, three years after the association’s foundation and to compare the melanomas histopathological characteristics to those documented in existing literature. Methods: A survey was shared via Google® Form with all the members of the association’s Facebook® account between November 26, 2024 to December 26, 2024. Results: A total of 85 general practitioners responded the survey. They reported the detection of 266 melanomas, corresponding to approximately 1.6 per year of dermoscopy practice in median (mean: 2,9). Thirty nine point five percent of detected melanomas (105/266) were in situ, while only 22,4% (36/161) had a Breslow thickness above 1mm, which constitute a substantial improvement compared to previously reported data on GP-detected melanomas. Conclusions : Empowerment of primary care medicine through dermoscopy learning appears to be a promising way to overcome the relative shortage of diagnostic offer observed in several countries. Integrating skin cancer screening into GPs practice may contribute to melanoma early detection and support ongoing efforts to lower melanoma mortality.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (12)

Martyna Sławińska

University Clinical Centre

POLAND
View details

Grazyna Kaminska-Winciorek

Full Prof. M.D.Ph.D.,MBA, scientific position; Head of the Skin Cancer and Melanoma Team in MSCNRIO, Gliwice Branch; medical consultant

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND
View details

Claus Garbe

Professor of Dermatology

Eberhard Karls Universität Tübingen

GERMANY
View details

Michał Kunc

Pathologist

Medical University of Gdansk

POLAND
View details

Jakub Karol Żółkiewicz

Medical University of Gdansk

POLAND
View details

Aimilios Lallas

Associate Professor

Aristotle University of Thessaloniki

GREECE
View details

Evelyne Harkemanne

UCLouvain

BELGIUM
View details

Grant McArthur

Lorenzo Galli Chair of Melanoma and Skin Cancers

University of Melbourne

AUSTRALIA
View details

Samy Belkaïd

Université Claude Bernard Lyon 1

FRANCE
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details

allan halpern

Chief of Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Giovanni Pellacani

Full Professor

Università degli Studi di Roma La Sapienza

ITALY
View details